Document Detail


Pitting the FDA Against CMS: The good, the bad, and the ugly about "parallel review.".
MedLine Citation:
PMID:  22479222     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The good, the bad, and the ugly about the FDA/CMS parallel review process. Can it work?
Authors:
Stephen Barlas
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biotechnology healthcare     Volume:  8     ISSN:  1554-169X     ISO Abbreviation:  Biotechnol Healthc     Publication Date:  2011  
Date Detail:
Created Date:  2012-04-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101241418     Medline TA:  Biotechnol Healthc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  29-30     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher st...
Next Document:  How Will Biologics Fit Into Healthcare Reform?: With so many variables, it's hard to predict what ki...